SecBot SecBot
SECBOTREPLAY Home › Report › BCRX

BCRX · BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23…

BIOCRYST PHARMACEUTICALS INC · 8-K filed Aug 5, 2026 at 07:02 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 5, 2026 at 07:02 ET

BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23 consensus by 30.4%, and total revenue of $218.3M, beating the $183.3M estimate by 19.1%. The beat was driven by a $55.7M navenibart licensing fee from Neopharmed Gentili, while core ORLADEYO revenue grew only 1% YoY to $158.2M. The company raised total revenue guidance to $690M-$715M and lowered non-GAAP opex guidance, but maintained ORLADEYO guidance at $625M-$645M, signaling the core business is not accelerating.

  • GAAP EPS of $0.30 beat consensus of $0.23 by 30.4%
  • Total revenue of $218.3M beat consensus of $183.3M by 19.1%
  • ORLADEYO revenue of $158.2M grew only 1% YoY (10% on comparable basis ex-Europe)
  • Recognized $55.7M of navenibart licensing revenue from Neopharmed Gentili upfront payment

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access